Top
Main
 
All Outcomes
 
RCT vs. Obs.
 
Feedback
Home
c19early.org COVID-19 treatment researchSpironolactoneSpironolactone (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Spironolactone for COVID-19: real-time meta analysis of 12 studies

@CovidAnalysis, November 2024, Version 13V13
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 77% 0.23 [0.08-0.66] recov. time 8 (n) 262 (n) Improvement, RR [CI] Treatment Control Cadegiani 83% 0.17 [0.06-0.51] recov. time 8 (n) 262 (n) Cadegiani 38% 0.62 [0.42-0.91] viral time 8 (n) 262 (n) Mareev (RCT) 11% 0.89 [0.65-1.22] no recov. 33 (n) 33 (n) CT​1 Mareev (RCT) 39% 0.61 [0.14-0.97] no recov. 14/24 20/21 CT​1 Mareev (RCT) 8% 0.92 [0.77-1.09] hosp. time 33 (n) 33 (n) CT​1 Mareev (RCT) 87% 0.13 [0.01-2.25] viral+ 0/17 3/13 CT​1 Ersoy (ICU) 46% 0.54 [0.36-0.81] death 14/30 26/30 ICU patients Davarpanah 78% 0.22 [0.08-0.55] hosp. 6/103 23/103 CT​1 Davarpanah 67% 0.33 [0.16-0.71] progression 8/103 24/103 CT​1 Davarpanah 64% 0.36 [0.21-0.60] recov. time 103 (n) 103 (n) CT​1 Abbasi (SB RCT) 55% 0.45 [0.18-1.13] death 5/51 19/87 Abbasi (SB RCT) 34% 0.66 [0.30-1.48] ventilation 7/51 18/87 Abbasi (SB RCT) 19% 0.81 [0.42-1.59] ICU 10/51 21/87 Abbasi (SB RCT) 47% 0.53 [0.39-0.72] no recov. 51 (n) 87 (n) Wadhwa (RCT) 72% 0.28 [0.09-0.85] progression 4/74 9/46 Wadhwa (RCT) 49% 0.51 [0.27-0.95] no disch. 13/74 16/46 Wadhwa (RCT) 18% 0.82 [0.67-1.00] recov. time 74 (n) 46 (n) Mehrizi 32% 0.68 [0.65-0.72] death population-based cohort Holt -129% 2.29 [1.59-3.32] death/ICU 16/31 148/658 Jeon 77% 0.23 [0.08-0.64] cases case control MacFadden 7% 0.93 [0.88-0.98] cases n/a n/a Cousins (PSM) 81% 0.19 [0.06-0.65] ventilation 731 (n) 731 (n) Cousins (PSM) 66% 0.34 [0.17-0.68] ICU 731 (n) 731 (n) Cousins (PSM) 18% 0.82 [0.71-0.93] death 390/12,504 479/12,504 Cousins (PSM) 12% 0.88 [0.79-0.99] death 521/16,324 592/16,324 Cousins (PSM) 15% 0.85 [0.77-0.94] death 671/20,690 783/20,690 Cousins (PSM) 17% 0.83 [0.77-0.91] ventilation 936/12,504 1,118/12,504 Cousins (PSM) 17% 0.83 [0.77-0.89] ventilation 1,212/16,324 1,459/16,324 Cousins (PSM) 10% 0.90 [0.84-0.95] ventilation 1,524/20,690 1,701/20,690 Spironolactone COVID-19 outcomes c19early.org November 2024 1 CT: study uses combined treatment Favors spironolactone Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit